{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:15:52Z","timestamp":1774260952401,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejca.2025.115641","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:07:25Z","timestamp":1752599245000},"page":"115641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO"],"prefix":"10.1016","volume":"227","author":[{"given":"Arvind","family":"Dasari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Garcia-Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7521-1596","authenticated-orcid":false,"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joleen","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-1699","authenticated-orcid":false,"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Schelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115641_bib1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2025.115641_bib2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.115641_bib3","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.2217\/fon-2021-0202","article-title":"FRESCO-2: a global phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer","volume":"17","author":"Dasari","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.115641_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115641_bib5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s40265-018-0998-z","article-title":"Fruquintinib: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejca.2025.115641_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10637-023-01395-y","article-title":"Phase 1\/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States","volume":"41","author":"Wang-Gillam","year":"2023","journal-title":"Invest New Drugs"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2025.115641_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.67","article-title":"Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study","volume":"41","author":"Sobrero","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115641_bib8","unstructured":"U.S. Food and Drug Administration. FRUZAQLA\u00ae (fruquintinib) prescribing information. Available at: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217564s000lbl.pdf\u3009. [Accessed 11 March 2024]."},{"key":"10.1016\/j.ejca.2025.115641_bib9","unstructured":"European Medicines Agency. FRUZAQLA\u00ae (fruquintinib) summary of product characteristics. Available at: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fruzaqla-epar-product-information_en.pdf\u3009. [Accessed 11 July 2024]."},{"key":"10.1016\/j.ejca.2025.115641_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/EDE.0000000000001517","article-title":"Profile matching for the generalization and personalization of causal inferences","volume":"33","author":"Cohn","year":"2022","journal-title":"Epidemiology"},{"key":"10.1016\/j.ejca.2025.115641_bib11","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2013.54.9329","article-title":"Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program","volume":"32","author":"Lieu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115641_bib12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12885-016-2440-9","article-title":"Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program","volume":"16","author":"Adenis","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.115641_bib13","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2023.41.16_suppl.3604","article-title":"Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer","volume":"41","author":"Dasari","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2025.115641_bib14","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1200\/JCO.2024.42.16_suppl.3579","article-title":"Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: results from FRESCO and FRESCO-2","volume":"42","author":"Bekaii-Saab","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115641_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jcph.70001","article-title":"Population pharmacokinetics of fruquintinib, a selective oral inhibitor of VEGFR -1, -2, and -3, in patients with refractory metastatic colorectal cancer","volume":"65","author":"Zhou","year":"2025","journal-title":"J Clin Pharm"},{"key":"10.1016\/j.ejca.2025.115641_bib16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejca.2025.115641_bib17","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/HYPERTENSIONAHA.120.16454","article-title":"Mechanisms underlying vascular endothelial growth factor receptor inhibition-induced hypertension: the HYPAZ trial","volume":"77","author":"M\u00e4ki-Pet\u00e4j\u00e4","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ejca.2025.115641_bib18","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1007\/s12325-020-01477-w","article-title":"Safety profile and adverse events of special interest for fruquintinib in Chinese patients with previously treated metastatic colorectal cancer: analysis of the phase 3 FRESCO trial","volume":"37","author":"Li","year":"2020","journal-title":"Adv Ther"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2025.115641_bib19","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2023.41.16_suppl.3601","article-title":"Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study","volume":"41","author":"Eng","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500423X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500423X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T13:36:57Z","timestamp":1771940217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492500423X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":19,"alternative-id":["S095980492500423X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115641","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Takeda Development Center Americas, Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115641"}}